Biologic drugs represent one of the most significant innovations in the treatment of autoimmune diseases like rheumatoid arthritis, Crohn’s disease, lupus, psoriasis, and many others. These conditions occur when the immune system mistakenly targets the body’s own cells, leading to chronic inflammation and tissue damage.
Unlike conventional drugs that act broadly and often non-selectively, biologics are designed to act precisely, targeting specific molecules involved in immune signaling. Instead of completely suppressing the immune system, biologics modulate its response, offering a more refined and often safer therapeutic strategy. However, this precision also brings new clinical challenges.
How Biologic Drugs Work
Biologics are highly specific proteins—most commonly monoclonal antibodies, fusion proteins, or cytokine inhibitors. Their production involves advanced biotechnological methods using living cells. While early biologics were derived from animal (mouse) proteins, modern versions are humanized to reduce immunogenicity—meaning the likelihood that the patient’s body will treat them as foreign substances.
These drugs often target cytokines—key messengers in immune communication. When overactive, cytokines like TNF-alpha, IL-6, or IL-17 contribute to chronic inflammation. Blocking them with drugs like infliximab or tocilizumab can significantly reduce symptoms and disease progression. Some biologics, such as abatacept and rituximab, target immune cells (T or B cells) directly, further fine-tuning immune regulation.
How the Body Processes Biologics
Unlike traditional small-molecule drugs, biologics cannot be taken orally—they would be destroyed by digestive enzymes. Instead, they are administered intravenously or subcutaneously. Absorption is fast via IV and slower via subcutaneous injection. Because of their size, biologics don’t easily cross into the brain or other protected compartments.
Their metabolism mimics the natural breakdown of proteins, involving the reticuloendothelial system (mainly the liver and spleen), rather than liver enzymes like CYP450. Some biologics, such as infliximab, bind strongly to plasma proteins, allowing them to stay in the bloodstream longer and be dosed less frequently—sometimes every few weeks.
Side Effects: Navigating Risk
Despite their selectivity, biologics can disrupt delicate immune balance. Immediate infusion reactions—rashes, itching, difficulty breathing, or low blood pressure—can occur due to sudden cytokine release or early immune sensitization. Delayed side effects may include skin reactions, serum sickness, or rare conditions like Stevens-Johnson syndrome.
Other complications may affect the nervous system (e.g., optic neuritis, MS-like syndromes), worsen existing heart failure, disrupt blood cell counts, or damage the liver. Long-term use, especially in combination with other immunosuppressants, may increase the risk of lymphoma.
When the Body Fights the Drug: Anti-Drug Antibodies (ADA)
One major challenge in biologic therapy is the body developing antibodies against the drug itself. These anti-drug antibodies can be:
-
Neutralizing: directly reduce drug efficacy
-
Non-neutralizing: may increase the risk of infusion reactions without affecting efficacy
Combining biologics with drugs like methotrexate can reduce this risk. Monitoring drug levels and ADA presence is increasingly important in personalizing treatment.
Supplements, Interactions and Lifestyle
Though biologics are not metabolized by liver enzymes, their effectiveness can still be influenced by drugs that impact liver function. Alcohol or poor nutrition can burden the liver, affecting safety. Supplements such as vitamin D, calcium, or omega-3s may help maintain immune balance and bone health, especially under prolonged immunosuppression.
Conclusion: Biologics as a Bridge Between Science and Trust
Biologic therapy embodies the shift toward personalized, precision medicine. Its successful use requires not only understanding immune mechanisms and pharmacology but also building trust with the patient, close clinical monitoring, and adaptability in treatment plans. Only when therapy is integrated with patient education and multidisciplinary care does the full potential of biologics emerge.
Prepared and written:
Mr.pharm. Romana Galin
Dr. Amira Ćerimagić, Clinical Immunologist
